ACS Chemical - American Chemical Society

---

Editorial pubs.acs.org/chemneuro

Reflections on 2016 and Projecting Forward he year 2016 was for a strong year for ACS Chemical Neuroscience, but 2017 promises to be even better. According to Thompson Reuters Web of Science, ACS Chemical Neuroscience manuscripts were cited an impressive 3045 times in 2016 (a new record) with cumulative 10 795 citations since Journal launch, and an h-index of 39.1 Only a quarter through 2017, and we already have over 1000 citations. The Journal also had a number of highly read (and tweeted) Editorials and Viewpoints that seemed to resonate with the community. The CNS MPO approach from Pfizer was first detailed in the inaugural volume of ACS Chemical Neuroscience in 2010 (and our most cited manuscript to date),2 and an update with real world application to drug discovery published in 2016 (and very highly read/cited as well).3 Excitingly, at every meeting I attend, people are showing/discussing CNS MPO scores for their compoundsthis concept is really influencing the community at large. There has been a marked increase in the “Classics in Chemical Neuroscience” Review articles, and we have expanded this to include highly valuable clinical tools and preclinical proof of concept tools as well as marketed CNS drugs that revolutionized patient care. Thus far, in 2017, xanomeline, abilify, ketamine and haloperidol have been reviewed. I would love to see more submissions of this type! Also, I want to expand this to include non-small molecule “Classics” and hope that neuropharmacologists would contribute “Classics” style reviews on key assays, technologies, behavioral assays/ paradigms that transformed CNS research or key genetic mouse models prevalent in the field. For example, great “Classics” topics could discuss: cell-based functional assays for identifying allosteric modulators, electrophysiology protocols or key behavioral paradigms such as psychostimulant-induced hyperlocomotion, psychostimulant-induced/genetic prepulse inhibition, contextual fear conditioning and addiction models (self-administration, etc.), etc. All of these would follow the standard “Classics” format (e.g., “Classics in Chemical Neuroscience: XYZ”) and give the reader a holistic view of the topic and the role and importance in neuroscience. These would be highly read and cited contributions. 2017 and 2018 hold a number of exciting special issues, beyond the February Monitoring in Molecules (edited by AE Anne Andrews) focused on Serotonin (edited by AE Anne Andrews), Precision Medicine in Brain Cancer (edited by Carol Nilsson/Kathryn Cunningham (AE)), Model Systems in Neuroscience (edited by Jonathan Sweedler/Elena Romanova), and Neuroplasticity (edited by Jeff Conn and Jerri Rook). ACS Chemical Neuroscience will also expand further into CNS oncology and infectious diseases of the CNS (for which we published several excellent Viewpoints in 2016/2017 on the brain-eating amoeba). I would love to have a special issue on neuropeptides and another on neurosteroidsif interested as serving as a guest editor, please email me (craig.lindlsey@ vanderbilt.edu). Finally, we are making a big push for global neuroscience, and just featured a new virtual issue on “Neuroscience in

T

© 2017 American Chemical Society

Brazil”many more will follow. We are also working to identify a new AE in China, as neuroscience there is growing at a dramatic rate, and the science is tremendous. In closing, thanks again to all the AEs, authors, and reviewersACS Chemical Neuroscience is on-track to do phenomenal things in 2017 and beyond!

■

Craig W. Lindsley, Editor-in-Chief AUTHOR INFORMATION

ORCID

Craig W. Lindsley: 0000-0003-0168-1445 Notes

Views expressed in this editorial are those of the author and not necessarily the views of the ACS.

■

REFERENCES

(1) http://apps.webofknowledge.com. (2) Wager, T. T., Hou, X., Verhoest, P. R., and Villalobos, A. (2010) Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties. ACS Chem. Neurosci. 1, 435−439. (3) Wager, T. T., Hou, X., Verhoest, P. R., and Villalobos, A. (2016) Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery. ACS Chem. Neurosci. 7, 767−775.

Published: June 21, 2017 1117

DOI: 10.1021/acschemneuro.7b00146 ACS Chem. Neurosci. 2017, 8, 1117−1117